{"id":"pegademase","brandName":"pegademase","genericName":"pegademase","companyId":"unknown","companyName":"","phase":"unknown","status":"active","modality":"","aliases":[],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"","enrichmentLevel":3,"visitCount":0,"mechanism":{},"administration":{},"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":["NCT02999984","NCT03765632","NCT01346150","NCT01852071","NCT01380990","NCT01186913","NCT03878069","NCT00794508","NCT01420627","NCT00001255"],"indications":{"approved":[{"name":"Adenosine deaminase deficiency","diseaseId":"adenosine-deaminase-deficiency","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"commercial":null,"patents":[],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[{"nctId":"NCT02999984","phase":"Phase 1","title":"Efficacy and Safety of Cryopreserved Formulation of Autologous CD34+ Hematopoietic Stem Cells Transduced Ex Vivo With Elongation Factor 1 Alpha Shortened (EFS) Lentiviral Vector Encoding for Human ADA","status":"COMPLETED","sponsor":"University of California, Los Angeles","isPivotal":false,"enrollment":10,"indication":"Severe Combined Immunodeficiency Due to ADA Deficiency","completionDate":"2019-09-26"},{"nctId":"NCT03765632","phase":"Phase 1","title":"Efficacy and Safety of a Cryopreserved Formulation of Autologous CD34+ Haematopoietic Stem Cells Transduced ex Vivo With Elongation Factor 1α Short Form (EFS) Lentiviral Vector Encoding for Human ADA ","status":"COMPLETED","sponsor":"Great Ormond Street Hospital for Children NHS Foundation Trust","isPivotal":false,"enrollment":13,"indication":"Severe Combined Immunodeficiency Due to ADA Deficiency","completionDate":"2022-09-28"},{"nctId":"NCT01346150","phase":"N/A","title":"A Retrospective and Cross-Sectional Analysis of Patients Treated for SCID Since January 1,1968 (RDCRN PIDTC-6902)","status":"UNKNOWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","isPivotal":false,"enrollment":1007,"indication":"SCID, ADA-SCID","completionDate":"2023-08"},{"nctId":"NCT01852071","phase":"Phase 1","title":"Autologous Transplantation of Bone Marrow CD34+ Stem/Progenitor Cells After Addition of a Normal Human ADA Complementary DNA (cDNA) by the EFS-ADA Lentiviral Vector for Severe Combined Immunodeficienc","status":"COMPLETED","sponsor":"University of California, Los Angeles","isPivotal":false,"enrollment":46,"indication":"ADA-SCID","completionDate":"2018-08-27"},{"nctId":"NCT01380990","phase":"Phase 1","title":"Phase I/II, Historical Controlled, Open-label, Non-randomised, Single-centre Trial to Assess the Safety and Efficacy of EF1αS-ADA Lentiviral Vector Mediated Gene Modification of Autologous CD34+ Cells","status":"COMPLETED","sponsor":"Great Ormond Street Hospital for Children NHS Foundation Trust","isPivotal":false,"enrollment":36,"indication":"Adenosine Deaminase Deficiency, Severe Combined Immunodeficiencies (SCID)","completionDate":"2019-12-23"},{"nctId":"NCT01186913","phase":"N/A","title":"A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children With SCID Disorders (RDCRN PIDTC-6901)","status":"ENROLLING_BY_INVITATION","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","isPivotal":false,"enrollment":690,"indication":"Severe Combined Immunodeficiency (SCID), Leaky SCID","completionDate":"2028-09"},{"nctId":"NCT03878069","phase":"N/A","title":"Single Arm, Open-Label, Multicenter, Registry Study of Revcovi (Elapegademase-lvlr) Treatment in ADA-SCID Patients Requiring Enzyme Replacement Therapy","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","isPivotal":false,"enrollment":32,"indication":"Adenosine Deaminase Severe Combined Immunodeficiency","completionDate":"2023-01-18"},{"nctId":"NCT00794508","phase":"Phase 2","title":"MND-ADA Transduction of CD34+ Cells From the Bone Marrow Of Children With Adenosine Deaminase (ADA)-Deficient Severe Combined Immunodeficiency (SCID): Effect of Discontinuation of PEG-ADA and Marrow C","status":"COMPLETED","sponsor":"Donald B. Kohn, M.D.","isPivotal":false,"enrollment":10,"indication":"Severe Combined Immunodeficiency","completionDate":"2015-01"},{"nctId":"NCT01420627","phase":"Phase 3","title":"A Study of EZN-2279 (Polyethylene Glycol Recombinant Adenosine Deaminase [PEG-rADA]) Administered as a Weekly Intramuscular Injection in Patients With Adenosine Deaminase (ADA)-Deficient Combined Immu","status":"COMPLETED","sponsor":"Leadiant Biosciences, Inc.","isPivotal":true,"enrollment":7,"indication":"ADA-SCID, Adenosine Deaminase Deficiency","completionDate":"2019-05-29"},{"nctId":"NCT00001255","phase":"N/A","title":"Treatment of Severe Combined Immunodeficiency Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency With Autologous Lymphocytes of CD34+ Cells Transduced With a Human ADA Gene: A Natural History ","status":"COMPLETED","sponsor":"National Human Genome Research Institute (NHGRI)","isPivotal":false,"enrollment":10,"indication":"Severe Combined Immunodeficiency","completionDate":"2002-07"}],"genericFilers":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}